The W. Garfield Weston Foundation – Alzheimer’s Drug Discovery Foundation – Canada (ADDF-Canada) Grant
In November 2011, the Weston Brain Institute began a collaboration with the Alzheimer’s Disease Drug Foundation to support their “Program to Accelerate Clinical Trials” (PACT) in Canada for novel Alzheimer’s therapeutics. The entire pool of funding was awarded to one clinical trial assessing whether a particular hypertensive medication protects against neurodegeneration better than a more commonly prescribed alternative. In this study, angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), will be compared for the treatment of hypertension in patients with Alzheimer’s disease. The trial will be led by Dr. Sandra Black and the Toronto Dementia Research Alliance at the University of Toronto.
Sartans to slow Alzheimer’s disease: A randomized double-blind, face-to-face proof-of-concept study of angiotensin receptor blockers versus ACE inhibitors in hypertensive mild-moderate AD patients using ventricular enlargement as primary outcome
Different classes of anti‐hypertensive drugs may have different effects on the brain beyond just blood pressure control. In this study, angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers...